ArticleJournal of advanced research2026
Gymconopin C exhibits anti-non-small cell lung cancer effect by regulating miR-6777-5p/ADRB2 pathway to promote mitophagy.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A dual role for miR-210-3p in hypoxia-driven signaling and mitotic regulation in cancer.Molecular biomedicine · 2026Article
- The Construction and Preclinical Evaluation of Antitumor Activity of a Novel MIgG-OXA ADC in Lung Adenocarcinoma.Oncology research · 2026Article
- The antioxidant, N-acetyl-L-cysteine, affects beta cell oxidative stress, insulin secretion, and intracellular signaling pathways in MIN6 cells.Cell and tissue research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-small cell lung cancer (NSCLC) remains the leading cause of morbidity and mortality from malignant tumors in China with therapeutic limitations. Developing novel therapeutic agents and innovative treatment strategies is critical for advancing NSCLC management. Gymconopin C, a compound isolated from Bletilla striata, has demonstrated potential anti-NSCLC activity; However, the underlying mechanism remains elusive.
objectivesThis study aimed to decipher the anti-NSCLC mechanism of Gymconopin C by demonstrating its induction of PINK1/Parkin-mediated mitophagy via the miR-6777-5p/ADRB2 pathway, and to establish the fundamental regulatory role of miRNA/mRNA axis in NSCLC suppression. This study establishes a novel therapeutically targetable pathway and offers a mechanistically grounded candidate for NSCLC therapy.
methodsIntegrated in vitro and in vivo strategies were used to elucidate the anti-NSCLC mechanism of Gymconopin C. Inhibitory effects on two NSCLC cell lines were assessed using CCK-8 proliferation, transwell migration and invasion assays. Subsequently, transmission electron microscopy and mitochondrial functional analyses were conducted to assess mitophagy. Transcriptomic profiling revealed dysregulation of the miR-6777-5p/ADRB2 axis, and gain/loss-of-function experiments were performed to investigate its functional role in mitophagy. Finally, the therapeutic efficacy and pathway modulation were evaluated in vivo using zebrafish xenograft and murine ectopic tumor models.
resultsGymconopin C significantly inhibited the proliferation, migration and invasion of NSCLC cells; induced cell cycle arrest and enhanced apoptosis of A549 cells. Mechanistically, it modulated the miR-6777/ADRB2 axis to promote PINK/Parkin-mediated mitophagy, ultimately leading to NSCLC growth arrest in both in vivo and in vitro experiments.
conclusionGymconopin C exerts tumor-suppressive effects by activating PINK1/Parkin-mediated mitophagy via the miR-6777-5p/ADRB2 axis, highlighting its potential as a therapeutic agent for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.